Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1402474 | 0.85 | MAPT (0.61) | CYP3A4MAPTMAPK1TP53KDM4E | |
| SCHEMBL1402414 | 0.83 | MAPT (0.48) | CYP3A4MAPTMAPK1TP53KDM4E | |
| SCHEMBL11882012 | 0.82 | MAPT (0.48) | CYP3A4MAPTMAPK1TP53KDM4E | |
| SCHEMBL70595 | 0.81 | MAPT (0.57) | CYP3A4MAPTMAPK1TP53KDM4E | |
| SCHEMBL27770681 | 0.81 | MAPT (0.47) | CYP3A4MAPTMAPK1TP53KDM4E | |
| SCHEMBL9742294 | 0.80 | KDM4E (0.65) | CYP3A4MAPTMAPK1TP53KDM4E | |
| SCHEMBL12584714 | 0.79 | MAPT (0.46) | CYP3A4MAPTMAPK1TP53KDM4E | |
| SCHEMBL29421917 | 0.79 | MAOB (0.45) | CYP3A4MAPTMAPK1TP53KDM4E | |
| SCHEMBL5141870 | 0.79 | MAOB (0.45) | CYP3A4MAPTMAPK1TP53KDM4E | |
| SCHEMBL30364533 | 0.79 | MAPT (0.46) | CYP3A4MAPTMAPK1TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114615967-B | Two-component oxidation dyeing composition | 花王株式会社 | 2024-05-14 | — | — | CN | disclosed |
| CN-115160279-B | Benzopyrone compounds, pharmaceutical compositions and uses | 中国药科大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-115160279-A | Benzopyrone compound, pharmaceutical composition and application | 中国药科大学 | 2022-10-11 | — | — | CN | disclosed |
| EP-3430105-B1 | CARBOGEL ANODE MATERIALS AND METHOD FOR THEIR PREPARATION | UNIV JAGIELLONSKI (PL) | 2022-08-31 | — | — | EP | disclosed |
| US-11117802-B2 | Carbogel anode materials and method for their preperation | UNIWERSYTET JAGIELLONSKI (PL) | 2021-09-14 | — | — | US | disclosed |
| CN-108884394-B | Carbon gel anode material and preparation method thereof | 雅盖隆大学 | 2021-04-06 | — | — | CN | disclosed |
| US-10945991-B2 | Use and pharmaceutical composition for liver fibrosis prevention and/or treatment | COJET BIOTECH INC. (TW) | 2021-03-16 | — | — | US | disclosed |
| US-20200129475-A1 | USE AND PHARMACEUTICAL COMPOSITION FOR LIVER FIBROSIS PREVENTION AND/OR TREATMENT | COJET BIOTECH INC. (TW) | 2020-04-30 | — | — | US | disclosed |
| US-20190071311-A1 | CARBOGEL ANODE MATERIALS AND METHOD FOR THEIR PREPERATION | UNIWERSYTET JAGIELLONSKI (PL) | 2019-03-07 | — | — | US | disclosed |
| EP-3430105-A1 | CARBOGEL ANODE MATERIALS AND METHOD FOR THEIR PREPARATION | Uniwersytet Jagiello Ski (PL) | 2019-01-23 | — | — | EP | disclosed |
| US-20170014355-A1 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-01-19 | — | — | US | disclosed |
| WO-2013025984-A2 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY (US) | 2013-02-21 | — | — | WO | disclosed |
| CN-100560577-C | The synthetic method of the synthetic method of wogonin and intermediate thereof and intermediate | UNIV CHINA PHARMA (CN) | 2009-11-18 | — | — | CN | disclosed |
| US-7285687-B2 | Cannabinoids | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-10-23 | — | — | US | disclosed |
| US-7179800-B2 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070037890-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20050165259-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2005-07-28 | — | — | US | disclosed |
| US-20050159449-A1 | Cannabinoids | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2005-07-21 | — | — | US | disclosed |
| WO-2003091189-A1 | CANNABINOIDS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0094769-B1 | PREPARING 7-ALKOXYBENZOFURANS AND INTERMEDIATES USED THEREIN | THE UPJOHN COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014355-A1 | CANNABINOID RECEPTOR TREATMENTS | CNR1, CNR2, GPR18 | CYP3A4 1441/4885MAPT 4023/4885MAPK1 2337/4885 |
| US-10945991-B2 | Use and pharmaceutical composition for liver fibrosis prevention and/or treatment | GOT1, GOT2, GYS2 | CYP3A4 442/4885MAPT 4514/4885MAPK1 2593/4885 |
| US-20050165259-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | CNR1, CNR2, HRH4 | CYP3A4 596/4885MAPT 430/4885MAPK1 1021/4885 |
| US-20050159449-A1 | Cannabinoids | CNR1, CNR2, OPRL1 | CYP3A4 709/4885MAPT 264/4885MAPK1 1419/4885 |
| US-20200129475-A1 | USE AND PHARMACEUTICAL COMPOSITION FOR LIVER FIBROSIS PREVENTION AND/OR TREATMENT | GOT1, GOT2, GYS2 | CYP3A4 672/4885MAPT 4479/4885MAPK1 2708/4885 |
| US-20070037890-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | CNR1, CNR2, HRH4 | CYP3A4 596/4885MAPT 430/4885MAPK1 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.